Duke Researchers Receive Grant to Roll Out Next-Generation Coronavirus Vaccine
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded $17.5 million over three years to the Duke Human Vaccine Institute to develop a vaccine that protects against multiple types of coronaviruses and viral variants.
Dzirasa named to the National Academy of Medicine
Election to NAM is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Discovery of I-Shaped Antibody Opens New Avenue to HIV Vaccine
About 38 million people worldwide are living with AIDS. Pharmaceutical treatments can keep the disease in check, but a vaccine remains elusive despite decades of concerted effort. However, a recent discovery at the Duke Human Vaccine Institute (DHVI) brings the goal of an effective vaccine within reach.
Duke Scientist Awarded NIH Grant for Research Addressing Health Disparities
The National Institutes of Health (NIH) has awarded Susan D.
Komen Initiative Awards DCI & UNC Lineberger Teams $1.5M for MBC Research
National breast cancer organization Susan G. Komen announced, on Sept.
Duke University Awarded $1.2 million CISNET Funding
Duke University is one of three sites that have been awarded a total of $4.4 million National Institutes of Health/National Cancer Institute Cancer Intervention and Surveillance Modeling Network (C
After Decades of Research, Drug Developed at Duke Receives FDA Approval
On October 8, the FDA approved a regenerative medicine based on Louise Markert, M.D., Ph.D.'s, pioneering work as the only therapy
Duke Neuroscientist Co-Leads Massive Effort to Map Brain
Every great exploration refines the map, and in the case of the massive BRAIN initiative funded by the National Institutes of Health, that new draft of the map has just been released.
Racial Disparities in Lung Cancer Outcomes Erased by Equal Access to Top Treatments
Although Black lung cancer patients are more likely to die from their disease than white patients, they have better outcomes than whites when treated with immunotherapies that are now considered th